GlaxoSmithKline posts results of Phase 3 salbutamol safety study
Results for this study were first posted on ClinicalTrials.gov on October 6, 2026, for a Phase 3 trial that enrolled 471 participants. The study began May 31, 2024 and completed primary data collection on September 2, 2025.
Primary source
ClinicalTrials.gov results record, October 6, 2026
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
Machine-summarized from the source above; not independently reported. How we use automation